Accelerated and AI-Based Genomic Workflows On-Prem and in the Cloud

From waste disposal to promising biomarkers and therapeutic agents, exosomes and other extracellular vesicles are valuable in research due to their role as intercellular messengers in health and disease. While their translational applications appear unlimited, the study of exosomes is challenged by their small size and heterogenous nature. In this webinar you will learn more about the common methods for exosome research and the proficient tools that Miltenyi Biotec offers to isolate and analyze exosomes. Join to connect with us and hear more.

Digital transformation has affected the clinical phase of the drug development journey by improving efficiencies, patient engagement and allowing for utilization of computational and other technologies. This track will address topics such as data collection, flow, storage and analytics and digital transformation case studies in clinical phase and the potential for digital transformation in the preclinical phase. Preclinical in vivo phase is in the initial stages of engaging with digitization and digitalization, which presents opportunities for learning from clinical colleagues how to implement these technologies.

As it is with so many things in life, how we begin often sets the tone for the entire journey. Bioproduction endeavors are no different. Using robust reagents and developing reproducible procedures at the early stages of your bioprocess is critical to producing a safe and efficacious final product. Upstream process scientists are constantly trying to improve parameters such as growth conditions, media analysis, and optimizing cell lines to ease the burden on downstream purification steps. Determining the best way to begin your bioproduction journey takes a lot of experience and can often seem daunting. However, in this presentation, our panelists will tell us what’s necessary for those initial successful steps.

Antibody-drug conjugates (ADCs) were initially developed to provide a selective targeting mechanism for cytotoxic small molecule drugs with the goal of improving the therapeutic index in clinical practice. But despite a careful target selection and a high degree of specificity afforded through the antibody part of the ADC, a sufficiently improved therapeutic index has been challenging to achieve. It often remains a challenge to reach desirable efficacious doses with repeated cycles of treatment due to the toxicity profile induced by the cytotoxic warhead. The clinical landscape of ADC therapeutics in both hematological and solid cancers has grown in recent years considerably to nearly 600 clinical trials incorporating numerous ADC modalities. These new molecular entities utilize many different tumor-associated antigen targets, new conjugation technologies, and payload warheads of various mechanisms such as tubulin inhibitors, DNA damaging, topoisomerase inhibition, or DNA polymerase II inhibitors.